Management of Localized and Locally Advanced Disease: Difference between revisions
Urology4all (talk | contribs) |
Urology4all (talk | contribs) |
||
| Line 90: | Line 90: | ||
==== Indications for intervention (treatment or AS intensity) ==== | ==== Indications for intervention (treatment or AS intensity) ==== | ||
===== AUA ===== | |||
* '''<span style="color:#ff0000">2021 AUA (5)[https://www.auanet.org/guidelines/renal-cancer-renal-mass-and-localized-renal-cancer-guideline]:</span>''' | * '''<span style="color:#ff0000">2021 AUA (5)[https://www.auanet.org/guidelines/renal-cancer-renal-mass-and-localized-renal-cancer-guideline]:</span>''' | ||
*# '''<span style="color:#ff0000">Tumour size >3cm</span>''' | *# '''<span style="color:#ff0000">Tumour size >3cm</span>''' | ||
| Line 97: | Line 99: | ||
*# '''<span style="color:#ff0000">Clinical changes in patient/tumour factors</span>''' (e.g. infiltrative on imaging, suspicion of advanced T stage) | *# '''<span style="color:#ff0000">Clinical changes in patient/tumour factors</span>''' (e.g. infiltrative on imaging, suspicion of advanced T stage) | ||
*# '''<span style="color:#ff0000">Additional biopsy results</span>''' (e.g. unfavourable histology) | *# '''<span style="color:#ff0000">Additional biopsy results</span>''' (e.g. unfavourable histology) | ||
===== CUA ===== | |||
*'''2022 CUA (4)[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932428/]''' | |||
*#'''Growth of tumor to >4 cm''' | |||
*#'''Consecutive growth rate >0.5 cm/year''' | |||
*#'''Progression to metastases''' | |||
*#'''Patient’s choice''' | |||
==== <span style="color:#ff0000">Follow-up</span> ==== | ==== <span style="color:#ff0000">Follow-up</span> ==== | ||